Dental Education Guide

Patient factors

Osteoporosis and Dental Implants: What Bone Density Actually Predicts

Osteoporosis itself does not preclude dental implants — but the medications used to treat it can, and jaw bone density does affect surgical technique. This guide separates the disease from the drugs.

Reading time
7–9 min
Medically reviewed
Reviewed by a licensed dentist
Last updated
2026-06-01

Written by

Dental Education Guide Editorial Team

Editorial team

Medically reviewed by

Medical Review Board (External Clinical Advisors)

Medical review

Editorial review

Evidence Review Lead

Editorial review

Last reviewed:
2026-06-01
Last updated:
2026-06-01
Reading time:
7–9 min
Version:
1.0

Overview

Two different concerns get conflated under "osteoporosis and implants": the disease itself (low systemic bone mineral density) and the antiresorptive drugs commonly used to treat it (bisphosphonates, denosumab). The disease has only modest impact on implant survival in the literature. The drugs — particularly intravenous bisphosphonates — carry a small but serious risk of medication-related osteonecrosis of the jaw (MRONJ) that has to be discussed explicitly[1].

Does osteoporosis itself reduce implant success?

Most cohort studies and systematic reviews report implant survival in osteoporotic patients within a few percentage points of non-osteoporotic controls — not statistically different in many analyses[2]. The mandible in particular tends to retain dense cortical bone even when hip and spine density are low. What does change is the surgical technique: surgeons may use under-preparation of the osteotomy, tapered implants, and longer healing periods to compensate for softer bone, especially in the posterior maxilla.

The medication side — bisphosphonates and denosumab

Oral bisphosphonates (alendronate, risedronate, ibandronate) carry a low but non-zero risk of MRONJ after invasive dental procedures. The 2022 AAOMS position paper quantifies the risk as well under 1% for routine oral bisphosphonate users undergoing extraction or implant placement, rising with cumulative dose and duration (especially beyond 4 years)[1].

Intravenous bisphosphonates (zoledronate, pamidronate) used in oncology carry a substantially higher MRONJ risk and are a relative contraindication to elective implant surgery. Denosumab behaves similarly to high-dose bisphosphonates clinically but has a shorter duration of action.

A reasonable shared-decision approach

  • Document the drug, dose, route, and duration of any antiresorptive therapy.
  • For oral bisphosphonates < 4 years: proceed with informed consent and standard care.
  • For oral bisphosphonates > 4 years or any IV exposure: consult the prescribing physician; consider C-terminal telopeptide (CTX) testing where used locally.
  • Active oncology IV bisphosphonate / denosumab therapy: avoid elective implant surgery.
  • Pre-operative chlorhexidine, atraumatic technique, primary soft-tissue closure where feasible.

Frequently asked questions

Scientific references

  1. 1. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. (AAOMS). (2022). American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws — 2022 Update. J Oral Maxillofac Surg. 80(5):920-943. View source
  2. 2. Moraschini V, Poubel LA, Ferreira VF, Barboza ES. (2015). Evaluation of survival and success rates of dental implants reported in longitudinal studies with a follow-up period of at least 10 years: a systematic review. Int J Oral Maxillofac Surg. 44(3):377-88. View source
  3. 3. American Dental Association. (n.d.). Oral Health Topics: Implants. American Dental Association. View source